Saturn V Capital Management’s Immix Biopharma IMMX Stock Holding History

Saturn V Capital Management’s Portfolio IMMX Stock Details IMMX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$48M	Buy	4,658,429 +964,844	+26%	+$8.95M	6.89%	5
2026 Q1	$33.6M	Buy	3,693,585 +694,416	+23%	+$5.1M	6.09%	6
2025 Q4	$15.7M	Buy	+2,999,169	New	+$12.3M	2.88%	15

Other funds holding IMMX

Jupiter Topco New York $245B AUM

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Saturn V Capital Management's IMMX Position: Q2 2026 in Review

Saturn V Capital Management increased its Immix Biopharma (IMMX) stake by 26% in Q2 2026, buying an estimated $8.95M and bringing the position to 4,658,429 shares worth $48M. The position accounts for 6.89% of the portfolio, ranked #5.

Saturn V Capital Management first reported a position in IMMX in Q4 2025 and has held it in 3 quarters since. 109 funds tracked by Wall St. Rank hold IMMX as of Q2 2026.

Saturn V Capital Management held 4,658,429 shares of Immix Biopharma worth $48M as of Q2 2026.
Saturn V Capital Management bought 964,844 Immix Biopharma shares in Q2 2026, an estimated $8.95M.
Immix Biopharma made up 6.89% of Saturn V Capital Management's portfolio in Q2 2026, its #5 holding.
Saturn V Capital Management first reported a position in Immix Biopharma in Q4 2025 and has held it in 3 quarters since.
109 funds tracked by Wall St. Rank held Immix Biopharma as of Q2 2026.

Based on Saturn V Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.